May 13, 2020JTO Clinical and Research ReportsOpen Access

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors

View Full Paper

Ask AI

Bookmark

Abstract

To our knowledge, this is the largest report to confirm that the EGFR-A763_Y764insFQEA mutation is sensitive to clinically available first-, second-, third-generation, and in-development EGFR TKIs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vasconcelos et al. (2020) studied this question.

synapsesocial.com/papers/69dcc16189c4deb67d359859 https://doi.org/10.1016/j.jtocrr.2020.100051

View Full Paper

Ask AI

Bookmark

Abstract

To our knowledge, this is the largest report to confirm that the EGFR-A763_Y764insFQEA mutation is sensitive to clinically available first-, second-, third-generation, and in-development EGFR TKIs.

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors

Abstract

Discussion

Cite This Study

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors

Abstract

Discussion

Cite This Study

Keep reading

Keep reading